

Handwritten: A2
P1 Z is selected from the group consisting of substituted and unsubstituted aryl other than substituted and unsubstituted phenyl; or a pharmaceutically acceptable salt thereof.

Handwritten: A3
17. ~~8.~~ (amended) A compound according to claim ~~27~~ wherein Z is selected from the group consisting of unsubstituted phenyl; and mono-, di- and tri-substituted phenyl.

Handwritten: A4
10. ~~11.~~ (amended) A compound according to claim ~~27~~ wherein Z is substituted or unsubstituted indolyl, furyl, pyridyl or benzofuryl; or a pharmaceutically acceptable salt thereof.

Handwritten: A4
11. ~~12.~~ (amended) A compound according to claim ~~11~~ wherein Z is substituted or unsubstituted 3-indolyl; or a pharmaceutically acceptable salt thereof.

13. (amended) The compound 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-phenyl-2-pyrazoline; or a pharmaceutically acceptable salt thereof.

Handwritten: A5
19. ~~17.~~ (amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim ~~15~~ or ~~16~~, or a pharmaceutically acceptable salt thereof.


Handwritten: A5
20. ~~18.~~ (amended) A method for treating a cyclooxygenase-mediated disorder comprising administering to a patient in need of such treatment an effective amount of a compound according to claim ~~15~~ or ~~16~~, or a pharmaceutically acceptable salt thereof.

Handwritten: A5
21. ~~19.~~ (amended) A method for treating inflammation or an inflammation-mediated disorder comprising administering to a subject in need of such treatment an effective amount of a compound according to claim ~~15~~ or ~~16~~, or a pharmaceutically acceptable salt thereof.

~~22~~ 20. (amended) A method for treating a neoplasia comprising administering to a subject in need of such treatment an effective amount of a compound according to claim ~~15~~ or ~~16~~, or a pharmaceutically acceptable salt thereof.

~~23~~ 21. (amended) A method for treating an angiogenesis-mediated disorder administering to a subject in need of such treatment an effective amount of a compound according to claim ~~15~~ or ~~16~~, or a pharmaceutically acceptable salt thereof.


~~24~~ 22. (amended) A method for producing a compound of formula I



50390

ps wherein:

p1 the group X is selected from the group consisting of trihalomethyl, C₁-C₆ alkyl, and a radical of formula II:



50391

p1 wherein:

p2 wherein R₃ and R₄ are independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, C₁-C₆ alkyl, C₁-C₆ alkoxy; carboxy; C₁-C₆ trihaloalkyl; and cyano; and


p1 Z is selected from the group consisting of substituted and unsubstituted aryl, other than substituted and unsubstituted phenyl;

p1 the method comprising:

p2 (a) reacting a compound of the formula IV

[Handwritten scribbles]

50400



p1 wherein X and Z are so defined;

with 4-sulfamyl phenyl hydrazine or salt thereof; and


p2 (b) isolating a compound according to formula I from the reaction products.

28

25. (amended) A method according to claim 50 wherein the group X in the reactant compound of formula IV is a radical of formula II:

27

50401



[Handwritten 'Ab']

p5 wherein:

p1 wherein R₃ and R₄ are independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, C₁-C₆ alkyl, C₁-C₆ alkoxy; and carboxy.


29

26. (amended) An isolated optical isomer of a compound according to claim 15 or 16, or a pharmaceutically acceptable salt thereof.

Add the following new claims:

30

27. (new) A compound of the formula:




[Handwritten 'A']

50402

p5 wherein:

p1 X is a group of formula II:



50403


[Handwritten 'A']

p1 wherein:

p2 R₃ and R₄ are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; carboxy; C₁-C₆ trihaloalkyl; and cyano;


p1 Z is selected from the group consisting of substituted and unsubstituted aryl, and when Z is heteroaryl, it is selected from the group consisting of substituted and unsubstituted pyridyl, furyl, indolyl, benzothienyl, benzofuryl, imidazolyl, pyrazolyl, 2-thiazolyl, quinoliny and 4-(2-benzyloxazolyl); or a pharmaceutically acceptable salt thereof.

13/28. (new) A compound of the formula:



p5 wherein:

p1 X is a group of formula II:




p1 wherein:

p2 R₃ and R₄ are independently selected from the group consisting of hydrogen, C₁-C₆ alkyl and C₁-C₆ alkoxy;

p1 Z is selected from the group consisting of phenyl; phenyl monosubstituted with halogen, hydroxyl, nitro or carboxy; disubstituted phenyl; trisubstituted phenyl; and heteroaryl selected from the group consisting of substituted and unsubstituted pyridyl,

furyl, indolyl, benzothienyl, benzofuryl, imidazolyl, pyrazolyl, 2-thiazolyl, quinoliny and 4-(2-benzyloxazolyl); or a pharmaceutically acceptable salt thereof.

~~14~~ 29.(new) A compound according to claim ~~28~~¹³ wherein Z is the group



~~10420~~
wherein R₁ and R₂ are independently selected from the group consisting of fluorine, bromine, chlorine, C₁-C₃ alkyl, C₁-C₃ alkoxy, hydroxyl and nitro; or a pharmaceutically acceptable salt thereof.

~~13~~ 30.(new) A compound according to claim ~~28~~¹³ wherein Z is substituted or unsubstituted indolyl, furyl, pyridyl or benzofuryl; or a pharmaceutically acceptable salt thereof.

~~110~~ 31.(new) A compound according to claim ~~30~~¹³ wherein Z is substituted or unsubstituted 3-indolyl; or a pharmaceutically acceptable salt thereof.

~~131~~ 32.(new) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1.

~~142~~ 33.(new) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim ~~27~~⁶.

~~143~~ 34.(new) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim ~~28~~¹³.

34
35. (new) A method for treating a cyclooxygenase-mediated disorder comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

35
36. (new) A method for treating a cyclooxygenase-mediated disorder comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 27.


36
37. (new) A method for treating a cyclooxygenase-mediated disorder comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 28.

37
38. (new) A method for treating inflammation or an inflammation-mediated disorder comprising administering to a subject in need of such treatment an effective amount of a compound according to claim 1.

38
39. (new) A method for treating inflammation or an inflammation-mediated disorder comprising administering to a subject in need of such treatment an effective amount of a compound according to claim 27.

39
40. (new) A method for treating inflammation or an inflammation-mediated disorder comprising administering to a subject in need of such treatment an effective amount of a compound according to claim 28.

40
41. (new) A method for treating a neoplasia comprising administering to a subject in need of such treatment an effective amount of a compound of the formula:




50430

43

A

ps wherein:

p1 X is selected from the group consisting of trihalomethyl, C₁-C₆ alkyl, and a group of formula II:




ps wherein:

ps R₃ and R₄ are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C₁-C₆ alkyl; C₁-C₆ alkoxy; carboxy; C₁-C₆ trihaloalkyl; and cyano;


p1 Z is selected from the group consisting of substituted and unsubstituted aryl; or a pharmaceutically acceptable salt thereof.

44
2. (new) A method for treating an angiogenesis-mediated disorder administering to a subject in need of such treatment an effective amount of a compound of the formula:



ps wherein:

p1 X is selected from the group consisting of trihalomethyl, C₁-C₆ alkyl, and a group of formula II:



p1 wherein:

p2 R₃ and R₄ are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C₁-C₆ alkyl; C₁-C₆ alkoxy; carboxy; C₁-C₆ trihaloalkyl; and cyano;

p1 Z is selected from the group consisting of substituted and unsubstituted aryl; or a pharmaceutically acceptable salt thereof.

42
~~43~~.(new) A method according to claim ~~41~~ or ~~42~~ wherein Z is selected from the group consisting of substituted and unsubstituted heteroaryl; or a pharmaceutically acceptable salt thereof.

43
~~44~~.(new) A method according to claim ~~43~~ wherein Z is selected from the group consisting of substituted and unsubstituted indolyl, furyl, thienyl, pyridyl, benzofuryl, benzothienyl, imidazolyl, pyrazolyl, thiazolyl, benzothiazolyl, quinoliny, and 4-(2-benzyloxazolyl); or a pharmaceutically acceptable salt thereof.


44
~~45~~.(new) A method according to claim ~~44~~ wherein Z is substituted or unsubstituted 3-indolyl; or a pharmaceutically acceptable salt thereof.

45
~~46~~.(new) A method according to claim ~~41~~ or ~~42~~ wherein X is trifluoromethyl.

46
~~47~~.(new) A method according to claim ~~41~~ or ~~42~~ wherein X is a group according to formula II wherein R₃ and R₄ are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C₁-C₆ alkyl; C₁-C₆ alkoxy; carboxy; C₁-C₆ trihaloalkyl; and cyano; or a pharmaceutically acceptable salt thereof.

47
~~48~~.(new) A method according to claim ~~47~~ wherein Z is selected from the group consisting of unsubstituted phenyl; and mono-, di- and tri-substituted phenyl.


30
~~49~~.(new) An isolated optical isomer of a compound of the formula:



10460

p⁵ wherein:

p¹ X is selected from the group consisting of trihalomethyl, C₁-C₆ alkyl, and a group of formula II:




p¹ wherein:

p² R₃ and R₄ are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C₁-C₆ alkyl; C₁-C₆ alkoxy; carboxy; C₁-C₆ trihaloalkyl; and cyano;


p² Z is selected from the group consisting of substituted and unsubstituted aryl; or a pharmaceutically acceptable salt thereof.

50. (new) A method for producing a compound of formula I



p⁵ wherein:

p¹ the group X is a radical of formula II:



10463

p¹ wherein: